MARLBOROUGH, Mass. / Feb 21, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements.
The report highlights how Hologic’s purpose – to enable healthier lives everywhere, every day – drives a commitment to developing medical technology innovations that generate robust financial returns. This business strength enables Hologic to invest in groundbreaking programs to increase the well-being of women, their families and their communities.
“At Hologic, we believe the best companies don’t have to choose between sustainability and maximizing performance. As you will see from the breadth and depth of our initiatives, each objective is intimately connected to our business strategy because doing the right thing is fundamental to who we are,” said Hologic Chairman, President and CEO Steve MacMillan.
Hologic’s sustainability accomplishments in the company’s fiscal year 2022 included:
In the past year, Hologic’s sustainability impact was a key reason the company received recognition from the Drucker Institute, Dow Jones, Fast Company, the Shingo Institute, LinkedIn, Newsweek, The Boston Globe and The San Diego Union-Tribune.
*Reductions compared to 2020 levels.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s sustainability efforts. There can be no assurance that these efforts will be successful, benefit the company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
Last Trade: | US$71.65 |
Daily Change: | 0.89 1.26 |
Daily Volume: | 7,640,910 |
Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB